The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.

The present methods treat neurofibromatosis by administering to a subject perillyl alcohol or iso-perillyl alcohol The present methods also treat neurofibromatosis by administering to a subject a carbamate of perillyl alcohol, or a carbamate of iso-perillyl alcohol The perillyl alcohol carbamate may comprise perillyl alcohol conjugated with rolipram or temozolomide.

A compound having the structure set forth in Formula (I) and Formula (II): ##STR00001##
wherein the substituents Y, Z, A, B, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.

A MgF.sub.2—CaF.sub.2 binary system sintered body for a radiation moderator having a compact polycrystalline structure excellent in radiation moderation performance, especially neutron moderation performance, comprises MgF.sub.2 containing CaF.sub.2 from 0.2% by weight to 90% by weight inclusive, having a bulk density of 2.96 g/cm.sup.3 or more, and a bending strength of 15 MPa or more and a Vickers hardness of 90 or more as regards mechanical strengths.

An anti-cancer agent includes Au(I) purinyl, indolyl, or azaindolyl analogues encapsulated in sterically hindered phosphine ligands.

A method of increasing abundance of hematopoietic stem cells and progenitor cells and an adjuvant method of radiotherapy based treatment for radioprotection of the subject against γ-radiation toxicity and/or IR-induced death of cancer cells involving pharmaceutically effective dosages of chlorophyllin or a pharmaceutically acceptable salt thereof. The advancement is directed to selectively protect normal hematopoietic stem cells and/or sensitizes radio-resistant cancer cells to gamma radiation thereby lowering the risk of normal tissue radiation toxicity. The effective dose of the CHL formulation synergistically improves the outcome of radiotherapy for cancer when administered to the subject prior the radiotherapy for treating cancer. Also disclosed is kit having chlorophyllin containing therapeutic preparation for treating indications selected from reduction in hematopoietic stem cells and progenitor cells (HSPCs) and/or protection against whole body irradiation induced mortality.

The invention provides polymeric H-NOX proteins for the delivery of oxygen with longer circulation half-lives compared to monomeric H-NOX proteins. Polymeric H-NOX proteins extravasate into and preferentially accumulate in tumor tissue for sustained delivery of oxygen. The invention also provides the use of H-NOX proteins as radiosensitizers for the treatment of brain cancers.

Disclosed herein are methods of increasing response to radiation therapy in subjects afflicted with cancer. In some embodiments, the method comprises reducing the ability of an immune suppressor cell (e.g., MDSC) to migrate to the microenvironment of the cancer. In some embodiments, the method further comprises suppressing the migration of the immune suppressor cell to a non-malignant cell and/or suppressing the malignant transformation of the non-malignant cells.

Inhibitors of MDM2 and MDM2-related proteins and compositions containing the same are disclosed. Methods of using the MDM2 inhibitors in the treatment of diseases and conditions wherein inhibition of an interaction between p53 and MDM2 provides a benefit, like cancers, also are disclosed.

Disclosed herein are methods and compositions related to combination therapy for cancer. More specifically, several treatment modalities are used in combination to induce an effective anti-tumor immune response. The present invention relates generally to the treatment of human cancer and, more specifically, to use of several treatment modalities in combination to induce effective anti-tumor immune responses.